Developer docs
API playgroundTry for free, no card

Search company profiles

Acupath Laboratories

Full company profile

uuid000bitb

Namestring
Acupath Laboratories
Legal namestring
Acupath Laboratories, Inc.
Websiteurl
acupath.com
Company typeenum
Private
Founded yearint
1998
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPlainview, United States
HQ citystring
Plainview
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anatomic pathology services, molecular diagnostic testing, cancer biomarker testing, FISH genetic testing, digital pathology services
Industry5 codes
PRIMARYHLAFAMAA
Anatomic Pathology (Histopathology & Cytopathology)
SECONDARYHLAGAEAC
Anatomic Pathology & Histopathology (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Anatomic Pathology Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Laboratory Testing Services
TypeTransaction Fee
Description

Anatomic pathology testing services billed to insurance companies, Medicare, Medicaid, and directly to clients. Services include surgical pathology, FISH testing, molecular diagnostics, flow cytometry, and specialized cancer biomarker tests (URO17). Pricing varies by test type and billing model (TC only, PC only, or Global).

acupath.com
2TC/PC Services Partnership Model
TypeManaged Services
Description

Technical Component only (TC) or Professional Component only (PC) services offered to physician offices and pathology practices. With over 100 active TC/PC customers, Acupath is one of the largest providers nationwide. Maximizes financial and clinical benefits for practice pathology specimens.

acupath.com
3Histology Lab Development
TypeProfessional Services
Description

Consulting and implementation services to help physician practices establish on-site histology labs, including required applications, licensure, contracting, credentialing, and reimbursement collection.

acupath.com
4Direct/Client Billing
TypeTransaction Fee
Description

Aggressive pricing offered on all tests on both TC only and Global basis, where permissible by federal and state law.

acupath.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details2 tiers
1URO17 CPT 88360 bladder cancer biomarker test
ModelUnit PricingBilling cadencePer test
Notes

$119 (CMS rate) - significantly less than comparable tests on the market. Urine Cytology CPT 88112 = $68 (CMS rate) for comparison.

acupath.com
2Standard laboratory pathology services
ModelOtherBilling cadencePer test
Notes

In-network processing with most large commercial insurance plans, Medicaid HMO products. Out-of-network cases forwarded to strategic laboratory partner for in-network processing.

acupath.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1ACU-URO17
Description

FDA-recognized Breakthrough Device for bladder cancer biomarker detection using Keratin 17 (K17) antibody. Clinically proven for over 5 years with 99% NPV and 96% sensitivity for ruling in/out bladder cancer.

acupath.com
+3 more records
Core offering1 text field

Acupath Laboratories is a sub-specialized anatomic and molecular pathology laboratory providing diagnostic testing services including surgical pathology, FISH (Fluorescence In Situ Hybridization) genetic panels, molecular PCR infectious disease panels, flow cytometry/hematopathology, and proprietary cancer biomarker tests such as Acu-URO17 for bladder cancer. The lab serves physician offices, hospitals, NYS Article 28 ASCs, and commercial laboratories nationwide through multiple business models including TC/PC partnerships, direct/client billing, and histology lab development consulting, with 24-72 hour turnaround times on most tests.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 97% sensitivity for bladder cancer detection with UroVysion FISH
+7 more records
Product overview1 text field

Acupath Laboratories is a nationwide provider of sub-specialized anatomic and molecular pathology services offering a comprehensive portfolio of diagnostic products and testing services. The core offerings include AI-powered diagnostic tools (Acu-URO17 bladder cancer biomarker, ArteraAI Prostate Test, Vesta), digital pathology (Lumea+ platform), molecular PCR infectious disease panels (GI, UTI, Wound, Respiratory), FISH testing (AcuProbe panels for melanoma, prostate, bladder, esophageal cancer), flow cytometry/hematopathology, and traditional surgical pathology with extensive immunohistochemistry. The company operates TC/PC partnership models for physician practices and provides web-based reporting through AcuReview 2.0. Founded in 1998 and based in Plainview, NY, with over 250,000 specimens processed annually and 700+ active clients.

Product and service17 records
1Acu-URO17 Bladder Cancer Biomarker Test
CategoryCancer Biomarker Diagnostics
Description

FDA-recognized Breakthrough Device bladder cancer biomarker test that detects cytokeratin 17 (K17) expression in urine samples, used in conjunction with urine cytology and/or FISH to improve diagnosis and management of bladder cancer. Offers 99% NPV for ruling out and 96% sensitivity for detecting both low and high-grade urothelial carcinoma. Priced at $119 (CMS rate).

2ArteraAI Prostate Test
CategoryAI-Powered Cancer Diagnostics
Description

AI-powered prostate cancer risk stratification tool that analyzes digital pathology images of prostate biopsies to predict therapy benefit and forecast long-term outcomes in localized prostate cancer. The only tool in NCCN Clinical Practice Guidelines for both predictive functions, delivering results within 24 hours.

3Vesta AI Diagnostic Test
CategoryAI-Powered Cancer Diagnostics
Description

AI-powered diagnostic test for non-muscle invasive bladder cancer delivered through partnership with Valar Labs, providing advanced diagnostic solutions for improved bladder cancer management.

4AcuProbe FISH Panels
CategoryGenetic Cancer Testing
Description

Proprietary fluorescence in situ hybridization panels including UroVysion (bladder cancer detection with 97% sensitivity), PTEN ERG (prostate cancer), Barrett's Esophagus FISH, TERC FISH, PathVysion HER2/neu, and Melanoma FISH for genetic abnormality detection in solid tumors.

5Acu-UTI Molecular PCR Test
CategoryMolecular Infectious Disease Testing
Description

Molecular RT-PCR testing for urinary tract infections detecting 31 organisms and 26 resistance genes. NYSDOH approved, approximately 25% more sensitive than culture alone with 24-48 hour turnaround.

6Gastrointestinal Pathogen Panel (BioFire GI)
CategoryMolecular Infectious Disease Testing
Description

BioFire FilmArray PCR-based molecular infectious disease test detecting 22 pathogens simultaneously from stool samples with 98.5% sensitivity and 99.2% specificity. Detects 25%-36% more pathogens than traditional GI testing with ~1 hour run time.

7RSV, Flu A & Flu B PCR
CategoryMolecular Infectious Disease Testing
Description

PCR-based respiratory virus testing differentiating between RSV, Influenza A, and Influenza B from nasopharyngeal swabs with results within 24 hours.

8Wound Pathogen Panel
CategoryMolecular Infectious Disease Testing
Description

rt-PCR wound infection testing using 43 array-based assays to detect bacteria, fungi, and antibiotic resistance genes with results within 48 hours.

9Nail Pathogen Panel
CategoryMolecular Infectious Disease Testing
Description

rt-PCR testing detecting 16 pathogens from nail samples within 24-48 hours, 3.5 times more sensitive than traditional culture techniques with 98-100% pathogen certainty.

10Flow Cytometry and Hematopathology
CategoryHematopathology Diagnostics
Description

Immunophenotyping services using BD FACS Canto 10-color flow cytometry for diagnosis of chronic or acute B-cell, T-cell, Myeloid, or Plasma Cell Neoplasms with comprehensive 31 marker panels.

11Surgical Pathology
CategorySurgical Pathology
Description

Fine needle aspirations, surgical excisions, margin assessments, sentinel lymph node analysis, and sentinel node micrometastasis detection with ER/PR, Her2/neu, and MIB-1 (KI-67) testing.

12Special Stains & Antibody Markers
CategoryImmunohistochemistry Diagnostics
Description

Extensive immunohistochemistry panel including over 150 antibody markers for diagnostic and prognostic assessment across multiple tissue types and cancer applications.

13Dermatopathology
CategorySubspecialty Pathology
Description

Board-certified dermatopathologist interpretation of skin and soft tissue biopsies using shave, punch, or excision procedures with direct immunofluorescence, genetic FISH testing, and molecular T-cell gene rearrangement studies.

14Gastroenterology Pathology
CategorySubspecialty Pathology
Description

Expert interpretation of endoscopic biopsies and surgical specimens for upper and lower GI tracts with cytology, FISH, and specialized stains for H. pylori, HPV, and various GI markers.

15Uropathology
CategorySubspecialty Pathology
Description

Expert prostate, bladder, testis, and vas deferens biopsy interpretation with UroVysion, PTEN/ERG, and TERC FISH testing along with PSA testing and stone analysis.

16TC/PC Services Partnership Model
CategoryPathology Partnership Services
Description

Technical Component only (TC) or Professional Component only (PC) services offered to physician offices and pathology practices. With over 100 active TC/PC customers, Acupath is one of the largest providers of TC-only services nationwide, providing revenue-generating partnerships for physician practices.

17Histology Lab Development Consulting
CategoryPathology Partnership Services
Description

Consulting and implementation services to help physician practices establish on-site histology labs, including required applications, licensure, contracting, credentialing, and reimbursement collection. Includes NYS Article 28 ASC and CLEP certification guidance.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-28
Description

Acupath integrated the ArteraAI Prostate Test into its digital pathology diagnostic pathway, becoming the first pathology lab in New York to offer this AI-powered tool for localized prostate cancer. The test analyzes digital pathology images and delivers results within 24 hours, predicting therapy benefit and forecasting long-term outcomes.

2Azer Scientific
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2026-02-27
Description

Acupath partnered with Azer Scientific to install the first AzerView LH510 Digital Pathology Scanner in the United States. This marks a significant milestone for digital pathology and diagnostic innovation, enabling enhanced digital pathology workflow capabilities.

businesswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-03
Description

Strategic partnership to deliver Vesta, an AI-powered diagnostic test for non-muscle invasive bladder cancer. The partnership aims to provide advanced diagnostic solutions for improved bladder cancer management.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-20
Description

Lumea is the U.S. leader in primary clinical digital pathology. Acupath partnered with Lumea to adopt the Lumea+ Viewer and digital pathology platform, enabling seamless transition from traditional to digital pathology with improved biopsy handling, tracking, workflow, and diagnosis. The partnership also includes AI-powered quantification of the URO17 bladder cancer biomarker through AIRA Matrix's algorithms.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-20
Description

AIRA Matrix delivers AI-based diagnostic, prognostic, and predictive applications in cancer care. The partnership with Acupath and Lumea focuses on developing algorithms that automate quantification of the URO17 test, improving accuracy and turnaround time for bladder cancer diagnosis. The collaboration enhances pathologists' ability to make accurate diagnoses and improve treatment decisions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

National clinical laboratory incumbent with anatomic pathology, molecular, and infectious disease testing. COO Brian Kunkel's prior employer; competes with Acupath across virtually all test categories but operates at national scale with broad payor access.

TypeBroad incumbent
Description

Genomic profiling company owned by Roche providing comprehensive genomic testing in oncology. Listed as an Acupath vendor partner; competes indirectly on molecular oncology and companion diagnostics.

TypeRegional player
Description

International pathology operator with U.S. presence (e.g., ProPath, Aurora Diagnostics) offering sub-specialized anatomic pathology. Comparable in sub-specialty focus and TC/PC-style service models but with global scale.

TypeEmerging player
Description

Liquid biopsy and precision oncology company. Listed as an Acupath vendor partner; represents an emerging technology paradigm that may eventually compete with or complement tissue-based pathology workflows.

TypeEmerging player
Description

Molecular profiling company with MI Profile and ADAPT AI platforms in oncology. Listed as a vendor partner of Acupath, indicating overlap in molecular oncology testing with an AI-driven differentiation strategy comparable to Acupath's ArteraAI and Vesta integrations.

TypeDirect peer
Description

Oncology-focused clinical laboratory providing anatomic pathology, FISH, molecular, and flow cytometry services. Direct competitor in urologic and GI oncology diagnostics with overlapping FISH and molecular test menu.

TypeBroad incumbent
Description

Largest U.S. clinical laboratory network including anatomic pathology through Dianon and integrated oncology services. Competes with Acupath on routine anatomic pathology and increasingly on molecular oncology and companion diagnostics.

TypeBroad incumbent
Description

Anatomic pathology subsidiary of LabCorp providing sub-specialized surgical pathology. CSO John Cucci's prior employer; competes directly with Acupath in physician-office anatomic pathology but at vastly larger scale under the LabCorp umbrella.

TypeEmerging player
Description

Specialized molecular and FISH diagnostics laboratory serving community urologists and gastroenterologists. Highly comparable to Acupath's TC/PC and specialty FISH test offering, with overlapping urology and GI physician customer base.

10Miraca Life Sciences (now Inform Diagnostics)
TypeDirect peer
Description

Specialized anatomic pathology laboratory offering sub-specialty reads across multiple organ systems. Closely comparable to Acupath in test menu, sub-specialty focus, and TC/PC service model serving community physician practices.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acupath Laboratories

Anatomic Pathology Servicesacupath.com

Acupath Laboratories firmographics

Firmographics
Name
Acupath Laboratories
Legal name
Acupath Laboratories, Inc.
Website
https://acupath.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Acupath Laboratories industry classification

Industry
Product category
Anatomic Pathology Services
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAFAMAA
Anatomic Pathology (Histopathology & Cytopathology)
SECONDARYHLAGAEAC
Anatomic Pathology & Histopathology (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs

Keywords

  • Anatomic pathology services
  • Molecular diagnostic testing
  • Cancer biomarker testing
  • FISH genetic testing
  • Digital pathology services

Where Acupath Laboratories is headquartered

Location

Headquarters

HQ city
Plainview
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Acupath Laboratories business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Laboratory Testing Services: Anatomic pathology testing services billed to insurance companies, Medicare, Medicaid, and directly to clients. Services include surgical pathology, FISH testing, molecular diagnostics, flow cytometry, and specialized cancer biomarker tests (URO17). Pricing varies by test type and billing model (TC only, PC only, or Global).
  2. TC/PC Services Partnership Model: Technical Component only (TC) or Professional Component only (PC) services offered to physician offices and pathology practices. With over 100 active TC/PC customers, Acupath is one of the largest providers nationwide. Maximizes financial and clinical benefits for practice pathology specimens.
  3. Histology Lab Development: Consulting and implementation services to help physician practices establish on-site histology labs, including required applications, licensure, contracting, credentialing, and reimbursement collection.
  4. Direct/Client Billing: Aggressive pricing offered on all tests on both TC only and Global basis, where permissible by federal and state law.

Pricing tiers

ModelBillingPrice
Unit PricingPer testURO17 CPT 88360 bladder cancer biomarker test
OtherPer testStandard laboratory pathology services

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Acupath Laboratories product offering

Product offering

Core offering

Acupath Laboratories is a sub-specialized anatomic and molecular pathology laboratory providing diagnostic testing services including surgical pathology, FISH (Fluorescence In Situ Hybridization) genetic panels, molecular PCR infectious disease panels, flow cytometry/hematopathology, and proprietary cancer biomarker tests such as Acu-URO17 for bladder cancer. The lab serves physician offices, hospitals, NYS Article 28 ASCs, and commercial laboratories nationwide through multiple business models including TC/PC partnerships, direct/client billing, and histology lab development consulting, with 24-72 hour turnaround times on most tests.

Product overview

Acupath Laboratories is a nationwide provider of sub-specialized anatomic and molecular pathology services offering a comprehensive portfolio of diagnostic products and testing services. The core offerings include AI-powered diagnostic tools (Acu-URO17 bladder cancer biomarker, ArteraAI Prostate Test, Vesta), digital pathology (Lumea+ platform), molecular PCR infectious disease panels (GI, UTI, Wound, Respiratory), FISH testing (AcuProbe panels for melanoma, prostate, bladder, esophageal cancer), flow cytometry/hematopathology, and traditional surgical pathology with extensive immunohistochemistry. The company operates TC/PC partnership models for physician practices and provides web-based reporting through AcuReview 2.0. Founded in 1998 and based in Plainview, NY, with over 250,000 specimens processed annually and 700+ active clients.

Differentiator

Problem solved

Functional benefit

Brands

  • ACU-URO17: FDA-recognized Breakthrough Device for bladder cancer biomarker detection using Keratin 17 (K17) antibody. Clinically proven for over 5 years with 99% NPV and 96% sensitivity for ruling in/out bladder cancer.
  • Acu-UTI
  • BioFire GI Panel
  • COVID-19/Flu/RSV Testing

Products and services

  • Acu-URO17 Bladder Cancer Biomarker Test FDA-recognized Breakthrough Device bladder cancer biomarker test that detects cytokeratin 17 (K17) expression in urine samples, used in conjunction with urine cytology and/or FISH to improve diagnosis and management of bladder cancer. Offers 99% NPV for ruling out and 96% sensitivity for detecting both low and high-grade urothelial carcinoma. Priced at $119 (CMS rate).
  • ArteraAI Prostate Test AI-powered prostate cancer risk stratification tool that analyzes digital pathology images of prostate biopsies to predict therapy benefit and forecast long-term outcomes in localized prostate cancer. The only tool in NCCN Clinical Practice Guidelines for both predictive functions, delivering results within 24 hours.
  • Vesta AI Diagnostic Test AI-powered diagnostic test for non-muscle invasive bladder cancer delivered through partnership with Valar Labs, providing advanced diagnostic solutions for improved bladder cancer management.
  • AcuProbe FISH Panels Proprietary fluorescence in situ hybridization panels including UroVysion (bladder cancer detection with 97% sensitivity), PTEN ERG (prostate cancer), Barrett's Esophagus FISH, TERC FISH, PathVysion HER2/neu, and Melanoma FISH for genetic abnormality detection in solid tumors.
  • Acu-UTI Molecular PCR Test Molecular RT-PCR testing for urinary tract infections detecting 31 organisms and 26 resistance genes. NYSDOH approved, approximately 25% more sensitive than culture alone with 24-48 hour turnaround.
  • Gastrointestinal Pathogen Panel (BioFire GI) BioFire FilmArray PCR-based molecular infectious disease test detecting 22 pathogens simultaneously from stool samples with 98.5% sensitivity and 99.2% specificity. Detects 25%-36% more pathogens than traditional GI testing with ~1 hour run time.
  • RSV, Flu A & Flu B PCR PCR-based respiratory virus testing differentiating between RSV, Influenza A, and Influenza B from nasopharyngeal swabs with results within 24 hours.
  • Wound Pathogen Panel rt-PCR wound infection testing using 43 array-based assays to detect bacteria, fungi, and antibiotic resistance genes with results within 48 hours.
  • Nail Pathogen Panel rt-PCR testing detecting 16 pathogens from nail samples within 24-48 hours, 3.5 times more sensitive than traditional culture techniques with 98-100% pathogen certainty.
  • Flow Cytometry and Hematopathology Immunophenotyping services using BD FACS Canto 10-color flow cytometry for diagnosis of chronic or acute B-cell, T-cell, Myeloid, or Plasma Cell Neoplasms with comprehensive 31 marker panels.
  • Surgical Pathology Fine needle aspirations, surgical excisions, margin assessments, sentinel lymph node analysis, and sentinel node micrometastasis detection with ER/PR, Her2/neu, and MIB-1 (KI-67) testing.
  • Special Stains & Antibody Markers Extensive immunohistochemistry panel including over 150 antibody markers for diagnostic and prognostic assessment across multiple tissue types and cancer applications.
  • Dermatopathology Board-certified dermatopathologist interpretation of skin and soft tissue biopsies using shave, punch, or excision procedures with direct immunofluorescence, genetic FISH testing, and molecular T-cell gene rearrangement studies.
  • Gastroenterology Pathology Expert interpretation of endoscopic biopsies and surgical specimens for upper and lower GI tracts with cytology, FISH, and specialized stains for H. pylori, HPV, and various GI markers.
  • Uropathology Expert prostate, bladder, testis, and vas deferens biopsy interpretation with UroVysion, PTEN/ERG, and TERC FISH testing along with PSA testing and stone analysis.
  • TC/PC Services Partnership Model Technical Component only (TC) or Professional Component only (PC) services offered to physician offices and pathology practices. With over 100 active TC/PC customers, Acupath is one of the largest providers of TC-only services nationwide, providing revenue-generating partnerships for physician practices.
  • Histology Lab Development Consulting Consulting and implementation services to help physician practices establish on-site histology labs, including required applications, licensure, contracting, credentialing, and reimbursement collection. Includes NYS Article 28 ASC and CLEP certification guidance.

Quantifiable outcome

  • 97% sensitivity for bladder cancer detection with UroVysion FISH
  • +7 more outcomes

Companies that use Acupath Laboratories

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Acupath Laboratories technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability8 records

Feature6 records

Acupath Laboratories partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • ArteraAIcoreTechnology or Integration · 28 May 2026Acupath integrated the ArteraAI Prostate Test into its digital pathology diagnostic pathway, becoming the first pathology lab in New York to offer this AI-powered tool for localized prostate cancer. The test analyzes digital pathology images and delivers results within 24 hours, predicting therapy benefit and forecasting long-term outcomes.
  • Azer ScientificflagshipTechnology or Integration · 27 February 2026Acupath partnered with Azer Scientific to install the first AzerView LH510 Digital Pathology Scanner in the United States. This marks a significant milestone for digital pathology and diagnostic innovation, enabling enhanced digital pathology workflow capabilities.
  • Valar LabscoreStrategic or Co-development Partner · 3 December 2025Strategic partnership to deliver Vesta, an AI-powered diagnostic test for non-muscle invasive bladder cancer. The partnership aims to provide advanced diagnostic solutions for improved bladder cancer management.
  • LumeacoreTechnology or Integration · 20 March 2025Lumea is the U.S. leader in primary clinical digital pathology. Acupath partnered with Lumea to adopt the Lumea+ Viewer and digital pathology platform, enabling seamless transition from traditional to digital pathology with improved biopsy handling, tracking, workflow, and diagnosis. The partnership also includes AI-powered quantification of the URO17 bladder cancer biomarker through AIRA Matrix's algorithms.
  • AIRA Matrix Private LimitedcoreTechnology or Integration · 20 March 2025AIRA Matrix delivers AI-based diagnostic, prognostic, and predictive applications in cancer care. The partnership with Acupath and Lumea focuses on developing algorithms that automate quantification of the URO17 test, improving accuracy and turnaround time for bladder cancer diagnosis. The collaboration enhances pathologists' ability to make accurate diagnoses and improve treatment decisions.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Acupath Laboratories competitors and assessment

Company assessment

Broad incumbents

  • Quest Diagnostics: National clinical laboratory incumbent with anatomic pathology, molecular, and infectious disease testing. COO Brian Kunkel's prior employer; competes with Acupath across virtually all test categories but operates at national scale with broad payor access.
  • Foundation Medicine: Genomic profiling company owned by Roche providing comprehensive genomic testing in oncology. Listed as an Acupath vendor partner; competes indirectly on molecular oncology and companion diagnostics.
  • Laboratory Corporation of America (LabCorp): Largest U.S. clinical laboratory network including anatomic pathology through Dianon and integrated oncology services. Competes with Acupath on routine anatomic pathology and increasingly on molecular oncology and companion diagnostics.
  • Dianon Pathology (LabCorp): Anatomic pathology subsidiary of LabCorp providing sub-specialized surgical pathology. CSO John Cucci's prior employer; competes directly with Acupath in physician-office anatomic pathology but at vastly larger scale under the LabCorp umbrella.

Regional players

  • Sonic Healthcare USA: International pathology operator with U.S. presence (e.g., ProPath, Aurora Diagnostics) offering sub-specialized anatomic pathology. Comparable in sub-specialty focus and TC/PC-style service models but with global scale.

Emerging players

  • Guardant Health: Liquid biopsy and precision oncology company. Listed as an Acupath vendor partner; represents an emerging technology paradigm that may eventually compete with or complement tissue-based pathology workflows.
  • Caris Life Sciences: Molecular profiling company with MI Profile and ADAPT AI platforms in oncology. Listed as a vendor partner of Acupath, indicating overlap in molecular oncology testing with an AI-driven differentiation strategy comparable to Acupath's ArteraAI and Vesta integrations.
  • P4 Diagnostix (formerly Theranostix): Specialized molecular and FISH diagnostics laboratory serving community urologists and gastroenterologists. Highly comparable to Acupath's TC/PC and specialty FISH test offering, with overlapping urology and GI physician customer base.

Direct peers

  • NeoGenomics: Oncology-focused clinical laboratory providing anatomic pathology, FISH, molecular, and flow cytometry services. Direct competitor in urologic and GI oncology diagnostics with overlapping FISH and molecular test menu.
  • Miraca Life Sciences (now Inform Diagnostics): Specialized anatomic pathology laboratory offering sub-specialty reads across multiple organ systems. Closely comparable to Acupath in test menu, sub-specialty focus, and TC/PC service model serving community physician practices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Acupath Laboratories social profiles

Digital presence

Acupath Laboratories compliance and trust

Trust signal

Compliance9 records

Acupath Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acupath Laboratories leadership team

Management profile

Number of profiles

Profiles9 records

Acupath Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acupath Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acupath Laboratories

What does Acupath Laboratories do?

Acupath Laboratories is a sub-specialized anatomic and molecular pathology laboratory providing diagnostic testing services including surgical pathology, FISH (Fluorescence In Situ Hybridization) genetic panels, molecular PCR infectious disease panels, flow cytometry/hematopathology, and proprietary cancer biomarker tests such as Acu-URO17 for bladder cancer. The lab serves physician offices, hospitals, NYS Article 28 ASCs, and commercial laboratories nationwide through multiple business models including TC/PC partnerships, direct/client billing, and histology lab development consulting, with 24-72 hour turnaround times on most tests.

Is Acupath Laboratories a public or private company?

Acupath Laboratories is a private company. It is classified as management employee owned and is currently operating.

When was Acupath Laboratories founded?

Acupath Laboratories was founded in 1998. It employs 51 to 100 people.

Where is Acupath Laboratories based?

Acupath Laboratories is headquartered in Plainview, United States, in the North America region.

How does Acupath Laboratories make money?

Four revenue lines are on record. Laboratory Testing Services are the primary driver. The others are TC/PC Services Partnership Model, histology Lab Development and direct/Client Billing.

Who are Acupath Laboratories's main competitors?

Broad incumbents on record are Quest Diagnostics, Foundation Medicine, Laboratory Corporation of America (LabCorp) and Dianon Pathology (LabCorp). Sonic Healthcare USA is listed as a regional player. Emerging players are Guardant Health, Caris Life Sciences and P4 Diagnostix (formerly Theranostix). Direct peers are NeoGenomics and Miraca Life Sciences (now Inform Diagnostics).

Does Acupath Laboratories have an API?

No public API is recorded for Acupath Laboratories.

What industry is Acupath Laboratories in?

Acupath Laboratories's product category is Anatomic Pathology Services. Its primary akta.pro industry code is HLAFAMAA, Anatomic Pathology (Histopathology & Cytopathology), with a secondary code of HLAGAEAC, Anatomic Pathology & Histopathology (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
01netAcupath Laboratories Integrates AI-Powered Prostate Cancer Risk Stratification Tool into its Digital Pathology Diagnostic PathwayAcupath Laboratories announced the integration of the ArteraAI Prostate Test into its digital pathology diagnostic pathway, becoming the first pathology lab in New York to offer this AI-powered tool for localized prostate cancer. The test analyzes digital pathology images of prostate cancer biopsies and delivers results within 24 hours, helping clinicians and patients determine optimal treatment options by predicting therapy benefit and forecasting long-term outcomes. The ArteraAI Prostate Test is the only tool in NCCN Clinical Practice Guidelines that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer.BioSpaceAcupath Laboratories Integrates AI-Powered Prostate Cancer Risk Stratification Tool into its Digital Pathology Diagnostic PathwayAcupath Laboratories integrated the ArteraAI Prostate Test into its diagnostic workflows, enabling fast delivery of treatment insights for localized prostate cancer. The AI test analyzes biopsy images and returns results within 24 hours, and is the only test in NCCN guidelines that predicts therapy benefit and long-term outcomes.Business Wire BlogAcupath Laboratories, Inc. Partners with Azer Scientific to Install the First AzerView Digital Pathology Scanner in the United StatesAcupath Laboratories, Inc. partnered with Azer Scientific to install the first AzerView LH510 Digital Pathology scanner in the United States, marking a milestone in digital pathology adoption in the country. The scanner, manufactured by Vieworks, was installed at Acupath's facility in Plainview, New York, and is designed to enhance high-resolution imaging, workflow efficiency, and diagnostic confidence for pathology professionals. Biolyst Scientific, the parent company of Azer Scientific, highlighted the installation as part of its commitment to enabling innovation through its operating companies.PR NewswireAcupath Laboratories Inc. Launches the BioFire® FilmArray® Gastrointestinal Pathogen (GI) PanelAcupath Laboratories Inc. announced the launch of the BioFire FilmArray Gastrointestinal Pathogen Panel, an FDA-cleared PCR-based molecular test that detects 22 common gastroenteritis pathogens with results in approximately one hour. The panel offers 98.5% sensitivity and 99.2% specificity, representing a significant advancement over traditional testing methods which are described as inefficient and labor-intensive. The company, founded in 1998 and headquartered in Plainview, New York, processes over 500,000 specimens annually across multiple specialties.PR NewswireAcupath Laboratories Inc. Releases Results of White Paper Highlighting Clinical Utility of the Acu-URO17 Bladder Cancer BiomarkerAcupath Laboratories released a white paper on Sept. 5, 2023 detailing results from a large-scale internal study of its Acu-URO17 urine-based bladder cancer biomarker. The assay showed a 99.9% negative predictive value, 96% sensitivity and 82% specificity on high-grade urothelial cancer cases, consistent with three prior peer-reviewed studies. Acupath has performed over 25,000 tests since launching nationwide in 2019.PR NewswireAcupath Laboratories Partners With CLX Health to Provide COVID-19 PCR Test Processing Through the TrustAssure™ Global NetworkAcupath Laboratories announced a partnership with CLX Health to process COVID-19 PCR tests through the TrustAssure™ Global Network, enabling travelers in the New York City area to meet international entry requirements. This collaboration allows patients to book appointments and transmit compliance status directly to airlines via the TrustAssure platform. The move expands Acupath's testing services beyond its traditional cancer diagnostics business to support global travel needs.BizjBenasource to bring Covid tests to independent pharmaciesBenasource will bring Covid tests to independent pharmacies, with results delivered within 24 hours. The tests are administered at the pharmacy.PR NewswireAcupath Launches COVID19 Testing in NY and BeyondAcupath Laboratories, Inc. announced the launch of COVID-19 testing services using the FDA EUA-approved ThermoFisher TaqPath RT-PCR COVID-19 Combo kit, with results available within 24 to 48 hours. The testing targets three coronavirus genes (orf-1ab, S protein, and N protein) and is being expanded to the greater New York City area and beyond to support the region's reopening and meet new requirements for elective surgeries and healthcare facility employees. The company, founded in 1998 and based in Plainview, NY, processes over 150,000 specimens annually and specializes in sub-specialized anatomic pathology services.PR NewswireAcupath First Commercial Lab to Offer URO17™, Innovative New Bladder Cancer BiomarkerAcupath Laboratories announced it is the first commercial lab in the U.S. to offer KDx Diagnostics' URO17™ bladder cancer biomarker test, receiving New York State Department of Health approval in June 2019 under a semi-exclusive license. The URO17 test demonstrated 100% sensitivity and 90-96% specificity across two clinical studies, significantly outperforming conventional urine cytology screening which has limited sensitivity for bladder cancer detection. Bladder cancer affects 81,000 Americans annually with a 75% recurrence rate, making improved detection technology a clinically significant advancement for urology and pathology communities.PR NewswireAcupath Names Hillel Kahane, MD as Chief Medical Officer & Director of UropathologyAcupath Laboratories, Inc. announced the appointment of Dr. Hillel Kahane as Chief Medical Officer and Director of Uropathology, effective immediately. Dr. Kahane joins from Bostwick Labs where he served as Medical Director since 2007 and previously held roles at Dianon Pathology (LabCorp), bringing over 25 years of uropathology experience interpreting over one million prostate biopsies. In his new role, he will oversee Acupath's growing uropathology department and guide the company's nationwide expansion strategy.